Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Survival After Multimodal Treatment for Breast Cancer in Brazil: The Predominant Role of Clinical Stage and Treatment Response.

Clinical breast cancer·2026
Same author

Improving Affordability in Cancer Care for Resource-Limited Settings: Highlights From <i>JCO Global Oncology</i>.

American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting·2026
Same author

Cost-Effectiveness of the Oncotype DX Breast Recurrence Score Test in the Brazilian Private Health Care Sector.

JCO global oncology·2026
Same author

Budget Impact of the Oncotype DX Test in Early-Stage Breast Cancer for the Brazilian Private Health Care System.

JCO global oncology·2025
Same author

Disparities in cancer clinical trials among low- and middle-income countries: A 20-year analysis.

Cancer·2025
Same author

Real-World Treatment Patterns and Outcomes in Hormone Receptor Positive HER2 Negative Early-Stage Breast Cancer in a Private Community Oncology Practice of Brazil.

Clinical breast cancer·2025

Related Experiment Video

Updated: Jun 6, 2026

Tumorsphere Derivation and Treatment from Primary Tumor Cells Isolated from Mouse Rhabdomyosarcomas
09:21

Tumorsphere Derivation and Treatment from Primary Tumor Cells Isolated from Mouse Rhabdomyosarcomas

Published on: September 13, 2019

Rare tumors research in emerging countries.

Max S Mano1, Roberto J Arai, Paulo M G Hoff

  • 1Instituto do Câncer do Estado de São Paulo (ICESP), Faculdade de Medicine da Universidade de São Paulo (FMUSP), Brazil.

Rare Tumors
|December 9, 2010
PubMed
Summary

Rare tumors cause significant cancer mortality, yet treatment advances lag due to clinical trial challenges. This article explores these difficulties and the growing role of emerging nations in rare cancer research and drug development.

Keywords:
clinical trials.developing countriesrare tumors

More Related Videos

A Brain Tumor/Organotypic Slice Co-culture System for Studying Tumor Microenvironment and Targeted Drug Therapies
10:13

A Brain Tumor/Organotypic Slice Co-culture System for Studying Tumor Microenvironment and Targeted Drug Therapies

Published on: November 7, 2015

Related Experiment Videos

Last Updated: Jun 6, 2026

Tumorsphere Derivation and Treatment from Primary Tumor Cells Isolated from Mouse Rhabdomyosarcomas
09:21

Tumorsphere Derivation and Treatment from Primary Tumor Cells Isolated from Mouse Rhabdomyosarcomas

Published on: September 13, 2019

A Brain Tumor/Organotypic Slice Co-culture System for Studying Tumor Microenvironment and Targeted Drug Therapies
10:13

A Brain Tumor/Organotypic Slice Co-culture System for Studying Tumor Microenvironment and Targeted Drug Therapies

Published on: November 7, 2015

Area of Science:

  • Oncology
  • Clinical Research
  • Global Health

Background:

  • Rare tumors collectively contribute significantly to cancer mortality, particularly in developed nations.
  • Treatment progress for rare cancers lags considerably behind that of common cancer types.
  • Logistical challenges in conducting large-scale clinical trials impede rare cancer research.

Purpose of the Study:

  • To examine the reasons behind the stagnation in rare cancer treatment.
  • To explore the current and future role of emerging nations in rare tumor research.
  • To discuss the drug development process for rare tumor types.

Main Methods:

  • Literature review and analysis of clinical trial challenges in rare diseases.
  • Examination of cancer incidence and research trends in emerging economies.
  • Discussion of drug development pathways for rare tumors.

Main Results:

  • Significant mortality burden from rare tumors, up to 25% in some nations.
  • Limited progress in rare cancer treatment due to inherent research difficulties.
  • Emerging nations show increasing potential in cancer research and drug development.

Conclusions:

  • Addressing logistical hurdles in clinical trials is crucial for advancing rare cancer care.
  • Emerging nations are poised to play an increasingly vital role in rare tumor research and therapeutic development.